Hualan Biological Bacterin Inc.

Hualan Biological Bacterin announced that its novel influenza virus mRNA vaccine has received clinical trial approval from the National Medical Products Administration, with a registration classification of preventive biological product 1.2, allowing clinical trials for the prevention of influenza caused by influenza viruses. The company stated that the product uses an mRNA technology platform, featuring flexible antigen design and a short production cycle, with potential in addressing influenza virus antigenic variation. As of the announcement date, no influenza mRNA vaccine has been approved for marketing in China, making Hualan Vaccine the first domestic company to obtain implied clinical trial approval for this type of product. Overseas, Moderna's influenza mRNA vaccine was approved by the U.S. FDA in August 2026. The company cautioned that vaccine development is difficult and lengthy, requiring subsequent clinical trials and marketing application procedures, and that product approval and market promotion remain uncertain.

Hualan Vaccine announced on August 28 that it plans to distribute a cash dividend of 1 yuan, tax included, for every 10 shares to all shareholders, with an estimated total payout of 59.5 million yuan. In the first half of 2026, the company achieved revenue of 44.39 million yuan and net profit attributable to the parent of 36.44 million yuan.

Multiple regions have released procurement intentions for the 2026 to 2027 flu season, with the budget unit price for trivalent influenza split-virus vaccine at approximately 9 yuan per dose. According to an incomplete tally by Red Star Capital Bureau, as of press time no fewer than 10 provinces have issued relevant procurement intentions, mainly targeting key groups such as rural residents aged 65 and above and primary and secondary school students in compulsory education. The main vaccine type procured is the 0.5 milliliter trivalent influenza split-virus vaccine for adults and children aged three and above. Among them, Hunan Province plans to procure 3.7611 million doses with a budget of 33.84 million yuan; Hubei Province plans to procure 2.8135 million doses with a budget of 25.32 million yuan; Heilongjiang Province plans to procure 1.0264 million doses with a budget of 9.2374 million yuan. Although Anhui, Hainan, Shaanxi and other regions have not disclosed specific dose numbers, they have listed budgets of 30.42 million yuan, 4.77 million yuan and 18.3425 million yuan respectively. This budget price has stabilized from last year's low of 5.5 yuan per dose, while the price of quadrivalent flu vaccines in the self-pay market remains relatively stable, with adult pre-filled syringes priced between 85 and 88 yuan per dose.